Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 201–300 of 2,039
Vadher, K., Patel, H., Mody, R., Levine, J. A., Hoog, M., Cheng, A. Y., Pantalone, K. M., & Sapin, H. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14775 · Cited by 56
Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems
Yang, B., Gelfanov, V. M., El, K., Chen, A., Rohlfs, R., DuBois, B., Kruse Hansen, A. M., Perez-Tilve, D., Knerr, P. J., D'Alessio, D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101638 · Cited by 55
Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog
Guo, W., Xu, Z., Zou, H., Li, F., Li, Y., Feng, J., Zhu, Z., Zheng, Q., Zhu, R., Wang, B., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101762 · Cited by 58
“This bias is thought to contribute the superior HbA1c reduction and weight loss results seen for tirzepatide compared to other GLP-1 receptor agonists [12,18].”
ResultQin, W., Yang, J., Ni, Y., Deng, C., Ruan, Q., Ruan, J., Zhou, P., & Duan, K. (2024) · Endocrine · doi:10.1007/s12020-024-03896-z · Cited by 55
“The estimated treatment differences in weight loss between the 5 ‐ mg, 10 ‐ mg, and 15 ‐ mg tirzepatide groups and the semaglutide 1 mg group were − 1.9, − 3.6, and − 5.5 kg, respectively [30].”
BackgroundInfluentialZhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01198-4 · Cited by 55
Aoun, L., Almardini, S., Saliba, F., Haddadin, F., Mourad, O., Jdaidani, J., Morcos, Z., Al Saidi, I., Bou Sanayeh, E., Saliba, S., et al. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100333 · Cited by 56
“Therefore, concerns about hypoglycemia and gastro-intestinal side effects should not prevent GLP-1RA treatment initiation or continuation for most patients, given the generally manageable safety and tolerability profile demonstrated in studies [28].”
BackgroundEffect of tirzepatide on blood pressure and lipids: a meta-analysis of randomized controlled trials
Kanbay, M., Copur, S., Siriopol, D., Yildiz, A. B., Gaipov, A., van Raalte, D. H., & Tuttle, K. R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15272 · Cited by 56
Management of metabolic-associated fatty liver disease: The diabetology perspective
Jeeyavudeen, M. S., Khan, S. K., Fouda, S., & Pappachan, J. M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i1.126 · Cited by 54
Legaard, G. E., Lyngbæk, M. P. P., Almdal, T., Karstoft, K., Bennetsen, S. L., Feineis, C. S., Nielsen, N. S., Durrer, C. G., Liebetrau, B., Nystrup, U., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00799-7 · Cited by 66
“However, as our findings are consistent with pharmacological weight-loss trials 37 , they may still have clinical implications.”
ResultDomingo, E., Marqués, P., Francisco, V., Piqueras, L., & Sanz, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107058 · Cited by 73
Li, M., Lin, H., Yang, Q., Zhang, X., Zhou, Q., Shi, J., & Ge, F. (2024) · SLEEP · doi:10.1093/sleep/zsae280 · Cited by 74
Xie, Z., Zheng, G., Liang, Z., Li, M., Deng, W., & Cao, W. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156038 · Cited by 54
Nestor, J. J., Parkes, D., Feigh, M., Suschak, J. J., & Harris, M. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-10577-2 · Cited by 53
Epicardial fat links obesity to cardiovascular diseases
Iacobellis, G. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.04.006 · Cited by 72
Caruso, I., Di Gioia, L., Di Molfetta, S., Cignarelli, A., Palmer, S. C., Natale, P., Strippoli, G. F. M., Perrini, S., Natalicchio, A., Laviola, L., et al. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102181 · Cited by 54
Apperloo, E. M., Tuttle, K. R., Pavo, I., Haupt, A., Taylor, R., Wiese, R. J., Hemmingway, A., Cherney, D. Z. I., Sattar, N., & Heerspink, H. J. L. (2025) · Diabetes Care · doi:10.2337/dc24-1773 · Cited by 53
Małecki, M. T., Batterham, R. L., Sattar, N., Levine, J. A., Rodríguez, Á., Bergman, B. K., Wang, H., Ghimpeteanu, G., & Lee, C. J. (2023) · Diabetes Care · doi:10.2337/dc23-1135 · Cited by 52
Self-citationThe expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 82
“Gastrointestinal adverse events such as nausea, diarrhea, constipation and vomiting are seen with all GLP-1 medicines and, to date, rates are similar with semaglutide versus tirzepatide 10,11,17 .”
Risk Factors, Clinical Consequences, Prevention, and Treatment of Childhood Obesity
Shaban Mohamed, M. A., AbouKhatwa, M. M., Saifullah, A. A., Hareez Syahmi, M., Mosaad, M., Elrggal, M. E., Dehele, I. S., & Elnaem, M. H. (2022) · Children · doi:10.3390/children9121975 · Cited by 52
Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents
Geisler, C. E., Antonellis, M. P., Trumbauer, W., Martin, J. A., Coskun, T., Samms, R. J., & Hayes, M. R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14843 · Cited by 51
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
Deng, Y., Park, A., Zhu, L., Xie, W., & Pan, C. Q. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221108064 · Cited by 51
Cariou, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14651 · Cited by 62
Mechano-energetic uncoupling in heart failure
Aksentijević, D., Sedej, S., Fauconnier, J., Paillard, M., Abdellatif, M., Streckfuß‐Bömeke, K., Ventura‐Clapier, R., van der Velden, J., de Boer, R. A., Bertero, E., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01167-6 · Cited by 60
“Tirzepatide, a combined GLP1 receptor and glucose-dependent insu-linotropic polypeptide (GIP) receptor agonist, is more efficient than semaglutide in reducing body weight in patients with obesity 359 , but mediated similar effects as those of semaglutide in patients with HFpEF and obesity 22 .”
Obesity pharmacotherapy in older adults: a narrative review of evidence
Henney, A. E., Wilding, J. P. H., Alam, U., & Cuthbertson, D. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01529-z · Cited by 51
“Cardiometabolic outcome trials: SURPASS-2 demonstrated greater ef fi cacy in the treatment of T2D compared to semaglutide in an older population (mean age 56.6 years, with no upper limit) [103].”
InfluentialMASLD treatment—a shift in the paradigm is imminent
Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51
Hormonal Gut–Brain Signaling for the Treatment of Obesity
Roh, E., & Choi, K. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043384 · Cited by 66
Gutgesell, R. M., Khalil, A., Liśkiewicz, A., Maity‐Kumar, G., Novikoff, A., Grandl, G., Liśkiewicz, D., Coupland, C., Karaoglu, E., Akindehin, S., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01294-x · Cited by 62
Tirzepatide: A Review in Type 2 Diabetes
France, N. L., & Syed, Y. Y. (2024) · Drugs · doi:10.1007/s40265-023-01992-4 · Cited by 51
Zaffina, I., Pelle, M. C., Armentaro, G., Giofrè, F., Cassano, V., Sciacqua, A., & Arturi, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1095753 · Cited by 56
“tirzepatide, supporting a dose-dependent safety profile (47, 48).”
BackgroundBeyond glycemia: Comparing tirzepatide to GLP-1 analogues
Andraos, J., Muhar, H. K., & Smith, S. R. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09825-1 · Cited by 59
“In SURPASS-2, tirzepatide 15 mg resulted in a 11.2 kg reduction in body weight versus 5.7 kg with 1 mg semaglutide (p 0.001) [46].”
BackgroundInfluentialCai, W., Zhang, R., Yao, Y., Wu, Q., & Zhang, J. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1277113 · Cited by 66
Treatment of OSA and its Impact on Cardiovascular Disease, Part 2
Javaheri, S., Javaheri, S., Gozal, D., Campos‐Rodríguez, F., Martínez‐García, M. Á., Mokhlesi, B., Mehra, R., McNicholas, W. T., Somers, V. K., Zee, P. C., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.07.024 · Cited by 54
Caruso, I., Di Gioia, L., Di Molfetta, S., Caporusso, M., Cignarelli, A., Sorice, G. P., Laviola, L., & Giorgino, F. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02441-z · Cited by 49
Yabe, D., Kawamori, D., Seino, Y., Oura, T., & Takeuchi, M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14882 · Cited by 48
Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes
Wang, L., Volkow, N. D., Kaelber, D. C., & Xu, R. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.26327 · Cited by 51
Lee, H. A., & Kim, H. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119324 · Cited by 48
Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence
Herman, R. J., & Schmidt, H. D. (2024) · Physiology & Behavior · doi:10.1016/j.physbeh.2024.114565 · Cited by 61
Quarenghi, M., Capelli, S., Galligani, G., Giana, A., Preatoni, G., & Quarenghi, R. T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113791 · Cited by 65
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 153
Krüger, N., Schneeweiss, S., Desai, R. J., Sreedhara, S. K., Kehoe, A. R., Fuse, K., Hahn, G., Schunkert, H., & Wang, S. V. (2026) · Nature Medicine · doi:10.1038/s41591-025-04102-x · Cited by 48
“Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist with rapidly growing use, has demonstrated even greater effects on glycemic control and weight loss 13–15 .”
Lee, C. J., Mao, H., Thieu, V. T., Landó, L. F., & Thomas, M. K. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad056 · Cited by 47
“Notably, in studies comparing tirzepatide with selective GLP-1 receptor agonists, tirzepatide delivered superior glycemic control and weight reduction in people with T2D [2, 6, 7].”
Self-citationXie, Z., Hu, J., Gu, H., Li, M., & Chen, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1244432 · Cited by 47
Melson, E., Miras, A. D., & Papamargaritis, D. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-0144 · Cited by 46
Caruso, I., & Giorgino, F. (2024) · Endocrine · doi:10.1007/s12020-024-03757-9 · Cited by 60
The Kidney in Obesity: Current Evidence, Perspectives and Controversies
Kounatidis, D. C., Vallianou, N. G., Stratigou, T., Voukali, M., Karampela, Ι., & Dalamaga, Μ. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00583-y · Cited by 56
“Indeed, tirzepatide has been documented to reduce body weight more than semaglutide among patients with DM in the SURPASS-2 clinical trial (-5.5 kg relative difference) [159].”
InfluentialGLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2192865 · Cited by 56
“In this respect, a reduced GIT side-effect profile with tirzepatide in T2DM is encouraging [73], suggesting prolonged treatment”
BackgroundInfluentialMüllertz, A. L. O., Sandsdal, R. M., Jensen, S. B. K., & Torekov, S. S. (2024) · Obesity Reviews · doi:10.1111/obr.13717 · Cited by 46
Jakubowska, A., Roux, C. W. L., & Viljoen, A. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1942 · Cited by 45
“However, about 11% of those with T2DM did not respond even to the highest dose of tirzepatide [53-55].”
BackgroundAchieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
Rosenstock, J., Vázquez, L., Del Prato, S., Franco, D. R., Weerakkody, G., Dai, B., Landó, L. F., Bergman, B. K., & Rodríguez, A. (2023) · Diabetes Care · doi:10.2337/dc23-0872 · Cited by 45
Self-citationThe role of GLP-1 receptor agonists in managing type 2 diabetes
Nachawi, N., Rao, P. P., & Makin, V. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21110 · Cited by 45
Agarwal, R., & Fouque, D. P. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac331 · Cited by 49
Mima, A., Nomura, A., & Fujii, T. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115032 · Cited by 49
Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?
Conceição-Furber, E., Coskun, T., Sloop, K. W., & Samms, R. J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.868037 · Cited by 48
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Andreasen, C. R., Andersen, A., & Vilsbøll, T. (2023) · Diabetologia · doi:10.1007/s00125-023-05966-9 · Cited by 44
“0 mg in type 2 diabetes, in doses of 5 mg, 10 mg and 15 mg, tirzepatide resulted in significantly greater body-weight reductions [5].”
BackgroundQassab, M. A., Mneimneh, M., Jradi, A., Derbas, B., Dabboussi, D., Baini, J. K., Katrib, N., Chaarani, N., Attieh, P., Kanaan, A., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040285 · Cited by 64
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70059 · Cited by 57
Xie, X., Yang, S., Deng, S., Liu, Y., Xu, Z., & He, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1613610 · Cited by 57
Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
Pοlyzos, S. A., Goulis, D. G., Γιουλεμέ, Ό., Germanidis, G. S., & Goulas, A. (2022) · Current Obesity Reports · doi:10.1007/s13679-022-00474-0 · Cited by 46
“Furthermore, tirzepatide also led to greater weight loss than GLP-1RAs, such as semaglutide, in patients with T2DM [82].”
BackgroundPatel, H., Khunti, K., Rodbard, H. W., Bajaj, H. S., Bray, R., Kindracki, Z., & Rodríguez, Á. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15333 · Cited by 43
Metabolic Messengers: glucagon
MacDonald, P. E., & Rorsman, P. (2023) · Nature Metabolism · doi:10.1038/s42255-022-00725-3 · Cited by 43
Pharmacological Support for the Treatment of Obesity—Present and Future
Kosmalski, M., Deska, K., Bąk, B., Różycka-Kosmalska, M., & Pietras, T. (2023) · Healthcare · doi:10.3390/healthcare11030433 · Cited by 67
Arvanitakis, K., Koufakis, T., Kotsa, K., & Germanidis, G. S. (2022) · Cancers · doi:10.3390/cancers14194651 · Cited by 63
“Although available data are still limited, tirzepatide has demonstrated impressive clinical benefits in recent trials, including the ability to return more than half of participants who received this agent to normoglycemia [87].”
BackgroundTirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist
Tall Bull, S., Nuffer, W., & Trujillo, J. M. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108332 · Cited by 43
Pulmonary aspiration of gastric contents in two patients taking semaglutide for weight loss
Avraham, S. A., Hossein, J., Somri, F., Hawash, N., & Hochman, O. (2024) · Anaesthesia Reports · doi:10.1002/anr3.12278 · Cited by 43
Knop, F. K., Urva, S., Rettiganti, M., Benson, C. T., Roell, W. C., Mather, K. J., Haupt, A., & Pratt, E. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15875 · Cited by 41
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“At dosages of 5, 10, and 15 mg, tirzepatide showed non-inferior treatment in glycemic control and superior behavior in weight loss than 1 mg semaglutide [85], further demonstrating the therapeutic efficacy of multi-agonists.”
BackgroundZaazouee, M. S., Hamdallah, A., Helmy, S. K., Hasabo, E. A., Sayed, A. K., Gbreel, M. I., Elmegeed, A. A., Aladwan, H., Elshanbary, A. A., Abdel‐Aziz, W., et al. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102511 · Cited by 45
Obesity pharmacotherapy: incretin action in the central nervous system
Boer, G. A., Hay, D. L., & Tups, A. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.11.001 · Cited by 51
Crawford, A. L., & Laiteerapong, N. (2024) · Annals of Internal Medicine · doi:10.7326/aitc202406180 · Cited by 54
Psaltis, J. P., Marathe, J., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22070 · Cited by 51
Tirzepatide for overweight and obesity management
Hamza, M., Papamargaritis, D., & Davies, M. J. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2436595 · Cited by 43
Self-citationXiang, L., Wang, G., Zhuang, Y., Luo, L., Yan, J., Zhang, H., Li, X., Xie, C., He, Q., Peng, Y., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.12.006 · Cited by 55
Structural pharmacology and mechanisms of GLP-1R signaling
Zhou, Q., Zhao, F., Zhang, Y., Yang, D., & Wang, M. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.03.003 · Cited by 52
Cesaro, A., Pastori, D., Acerbo, V., Biccirè, F. G., Golino, M., Panico, D., Prati, F., Abbate, A., Lip, G. Y. H., & Calabrò, P. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf257 · Cited by 56
Lam, C. S. P., Rodríguez, Á., Aminian, A., Ferrannini, E., Heerspink, H. J. L., Jastreboff, A. M., Laffin, L. J., Pandey, A., Ray, K. K., Ridker, P. M., et al. (2025) · Obesity · doi:10.1002/oby.24332 · Cited by 59
O'Keefe, J. H., Franco, W. G., & O'Keefe, E. L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.12.010 · Cited by 42
Bitsi, S., Eid, L. E., Manchanda, Y., Oqua, A. I., Mohamed, N., Hansen, B., Suba, K., Rutter, G. A., Salem, V., Jones, B. J., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf7737 · Cited by 46
Gasbjerg, L. S., Rosenkilde, M. M., Meier, J. J., Holst, J. J., & Knop, F. K. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15216 · Cited by 41
Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
Corrao, S., Pollicino, C., Maggio, D., Torres, A., & Argano, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1402583 · Cited by 62
Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis
Natividade, G. R., Spiazzi, B. F., Baumgarten, M. W., Bassotto, C., Pereira, A. A., Fraga, B. L., Scalco, B. G., Mattes, N. R., Lavinsky, D., Kramer, C. K., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.2489 · Cited by 41
Practice Patterns and Perspectives of the Off-Label Use of GLP-1 Agonists for Cosmetic Weight Loss
Han, S. H., Ockerman, K., Furnas, H., Mars, P., Klenke, A., Ching, J., Momeni, A., & Sorice-Virk, S. (2024) · Aesthetic Surgery Journal · doi:10.1093/asj/sjad364 · Cited by 40
Incretin-based investigational therapies for the treatment of MASLD/MASH
Brouwers, B., Rao, G., Tang, Y., Rodríguez, Á., Glass, L. C., & Hartman, M. L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111675 · Cited by 40
Papaetis, G. S., & Kyriacou, A. (2022) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/151695 · Cited by 58
Hinds, C. E., Peace, E., Chen, S., Davies, I., Eid, L. E., Tomás, A., Tan, T., MINNION, J. S., Jones, B. J., & Bloom, S. R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15288 · Cited by 42
Lupianez‐Merly, C., Dilmaghani, S., Vosoughi, K., & Camilleri, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17856 · Cited by 40
“94 A subgroup analysis from the SURPASS program was performed in Hispanic/ Latino vs non-Hispanic/Latino with T2DM, and there was no sig - nificant difference between groups taking tirzepatide in regards to safety outcomes, weight reduction and HbA1c improvement.”
MethodSemaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Salvador, R., Moutinho, C. M. S. G., Sousa, C., Vinha, A. F., Carvalho, M. C., & Matos, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18030399 · Cited by 55
Park, J. S., Kim, K. S., & Choi, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0106 · Cited by 59
Reagents and models for detecting endogenous GLP1R and GIPR
Ast, J., Broichhagen, J., & Hodson, D. J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103739 · Cited by 40
Valenzuela‐Vallejo, L., Guatibonza-García, V., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155248 · Cited by 44
Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lubel, J. S., Hodge, A., & Roberts, S. K. (2023) · Nutrients · doi:10.3390/nu15030687 · Cited by 48
Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus
Rodríguez Jiménez, B., Rodríguez de Vera Gómez, P., Belmonte Lomas, S., Mesa Díaz, Á. M., Caballero Mateos, I., Galán, I., Morales Portillo, C., & Martínez-Brocca, M. A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1386542 · Cited by 39
GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells
Shilleh, A. H., Viloria, K., Broichhagen, J., Campbell, J. E., & Hodson, D. J. (2024) · Peptides · doi:10.1016/j.peptides.2024.171179 · Cited by 39
“By contrast, tirzepatide was non-inferior and superior to the GLP1RA for glycated hemoglobin [113].”
Urkon, M., Ferencz, E., Szász, J. A., Szabó, M. I. M., Orbán-Kis, K., Szatmári, S., & Nagy, E. E. (2025) · Pharmaceuticals · doi:10.3390/ph18050614 · Cited by 45
“It proved to be superior to semaglutide in ameliorating T2DM and obesity-related outcomes [126].”
Permana, H., Yanto, T. A., & Hariyanto, T. I. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102640 · Cited by 38
Papaetis, G. S. (2023) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/161170 · Cited by 41
Falcão‐Pires, I., Ferreira, A. F., Trindade, F., Bertrand, L., Ciccarelli, M., Visco, V., Dawson, D. K., Hamdani, N., Laake, L. W. V., Lezoualc’h, F., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3264 · Cited by 50
New Molecules and Indications for GLP-1 Medicines
Gonzalez-Rellan, M. J., & Drucker, D. J. (2025) · JAMA · doi:10.1001/jama.2025.14392 · Cited by 50
Long-acting amylin analogues for the management of obesity
Mathiesen, D. S., Bagger, J. I., & Knop, F. K. (2022) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000716 · Cited by 36
“Compared with the current frontrunner from the pipeline of anti-obesity drugs, tirzepatide, the cagrilintide/semaglutide strategy is potentially on par or even superior in terms of weight loss with a similar safety profile [17,55,56].”
BackgroundScience-Driven Nutritional Interventions for the Prevention and Treatment of Cancer
Montégut, L., de Cabo, R., Zitvogel, L., & Kroemer, G. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0504 · Cited by 38
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.